Oestrogen-17-sulphamates as inhibitors of steroid sulphatase

Details Oestrogen-17-sulphamates as inhibitors of steroid sulphatase Oestrogen-17-sulphamates as inhibitors of steroid sulphatase

2006-10-10

2006-10-10

Qazi, Sabiha N. (Department: 1616)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S178000, C514S182000, C552S623000, C552S626000, C552S635000

Reexamination Certificate

active

07119081

ABSTRACT:
There is provided a compound of Formula Iwherein X is a ring system; R1is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; R2is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; wherein when X is a steroidal structure and both of R1and R2are sulphamate groups, the steroidal ring system (X) represents an oestrogen; and wherein said compound is capable of inhibiting steroid sulphatase (STS) activity and/or is capable of acting as a modulator of cell cycling and/or as a modulator of apoptosis and/or as a modulator of cell growth. There is also provided a compound of Formula VIIIwherein R2is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; and wherein said compound is capable of inhibiting steroid sulphatase (STS) activity and/or is capable of acting as a modulator of cell cycling and/or as a modulator of apoptosis and/or as a modulator of cell growth.

REFERENCES:
patent: 3951959 (1976-04-01), Prezewowsky et al.
patent: 6011024 (2000-01-01), Reed et al.
patent: 6017904 (2000-01-01), Reed et al.
patent: 6080735 (2000-06-01), Schwarz et al.
patent: 6087347 (2000-07-01), Koizumi et al.
patent: 6159960 (2000-12-01), Reed et al.
patent: 6339079 (2002-01-01), Kasch et al.
patent: 6593321 (2003-07-01), Rao et al.
patent: 6677325 (2004-01-01), Reed et al.
patent: B-29741/95 (1996-03-01), None
patent: 100 06 155 (2000-12-01), None
patent: 1479362 (1974-07-01), None
patent: 1479934 (1974-07-01), None
patent: 1482285 (1974-07-01), None
patent: 50-32160 (1975-03-01), None
patent: 50-32161 (1975-03-01), None
patent: WO 93/05064 (1993-03-01), None
patent: WO 96/05216 (1996-02-01), None
patent: WO 98/42729 (1998-01-01), None
patent: WO 99/64013 (1999-12-01), None
patent: WO 00/63228 (2000-10-01), None
patent: WO 01/44268 (2001-06-01), None
patent: WO 01/51055 (2001-07-01), None
patent: WO 01/77139 (2001-10-01), None
Woo, et al., “Oestrone 3-0-(N-Acetyl)Sulphamate, a Potential Molecular Probe of the Active Site of Oestrone Sulphatase,” Bioorganic & Medicinal Chemistry Letters, vol. 7, No. 24, pp. 3075-3080, 1997.
Romer, et al., “Preparation and characterization of the sulfamates of estra-3, 17.xi.-diols. Rapid conversion of 16.alpha.-fluoroestradiol-3, 17.beta.-disul famate”, J. Prakt. Chem. 1999, 341, No. 6.
Brunner, et al., “Synthese und Antitumoraktivitat von cis-Dichloroplatin(II)-Komplexen mit Ostradiolderivaten,” Monatshefte fur Chemie, vol. 124, No. 1, pp. 83-102 (1993).
Lokind, et al., “Oral bioavailability of 17.beta.-estradiol and produgs tested in rats, pigs and dogs,” Int. J. Pharm. (1996), 127(2), 155-64, abstract.
Nedvidkova, et al., “Estrogenic effect of estradiol-sulfamate on the male rat anterior pituitary,” J. Steroid Biochem. Mol. Biol. (1998), 67(4), abstract.
Kasch, et al., “In vitro selection of sulfatase inhibitors for tumor diagnosis with PET and for tumor therapy,” Wiss.-Tech. Ber.-Forschungszent. Rossendorf (1999), FZR-283, abstract.
Nussbaumer, et al., “4,4′-Benzophenone-O,O′-disulfamate: A Potent Inhibitor of Steroid Sulfatase,” Bioorganic & Medicinal Chemistry Letters 12 (2002) 2093-2095.
MacCarthy-Morrogh, et al., “Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic. Arrest, apoptosis, and microtubule assembly in human breast cancer cells,” Cancer Res 2000, 60 (19): 5441-50.
Schwarz, et al., “Synthesis of estrogen sulfamates: Compounds with a novel endocrinological profile,” Steroids, 61:710-717, 1996.
Romer, et al., “C NMR Spectroscopic Characterization of Some Sulfamates of 3-Hydroxy-estra-1,3,5(10)-triene Derivatives”.
Romer, et al., “Sulfamates of 3-Hydroxy-estra-1-3-5(10)-triene Derivatives”.
Reed, et al., “The development of steroid sulphatase inhibitors,” Endocrine-Related Cancer (1996) 3, 9-23.

Affiliated with

Also associated with

Rating

Oestrogen-17-sulphamates as inhibitors of steroid sulphatase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oestrogen-17-sulphamates as inhibitors of steroid sulphatase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oestrogen-17-sulphamates as inhibitors of steroid sulphatase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3637524